Caroline Emery

TL;DR: Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.

TL;DR: High-throughput genotyping is adapted to query 238 known oncogene mutations across 1,000 human tumor samples and established robust mutation distributions spanning 17 cancer types, offering a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time'.

TL;DR: The MEK1(C121S) mutation was shown to increase kinase activity and confer robust resistance to both RAF and MEK inhibition in vitro, and the use of emerging technologies in a manner that may accelerate personalized cancer medicine is illustrated.

TL;DR: The results affirm the importance of MEK dependency in BRAF-mutant melanoma and suggest novel mechanisms of resistance to MEK and B-RAF inhibitors that may have important clinical implications.

TL;DR: The implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting and demonstrates the clinical feasibility of high-throughput mutation profiling to query a large panel of “actionable” cancer gene mutations is reported.